Syndax Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Syndax Pharmaceuticals (Nasdaq: SNDX) announced that CEO Briggs W. Morrison will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 08:15 a.m. ET. The presentation will be available via live webcast on the Company’s Investor website, with replays accessible for a limited time. Syndax is a clinical stage biopharmaceutical company focusing on innovative cancer therapies, including SNDX-5613, axatilimab, and entinostat.

Positive

• Syndax has an innovative pipeline of cancer therapies.
• The company's leading drug candidates include SNDX-5613, axatilimab, and entinostat.

Negative

• None.

WALTHAM, Mass., Jan. 7, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 08:15 a.m. ET.

A live webcast of the presentation can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn.

Syndax Contacts

Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com 
Tel 212.600.1902

Media Contact
Benjamin Kolinski
benjamin.kolinski@gcihealth.com
Tel 862.368.4464

SNDX-G

 

View original content:https://www.prnewswire.com/news-releases/syndax-announces-presentation-at-40th-annual-jp-morgan-healthcare-conference-301456071.html

SOURCE Syndax Pharmaceuticals, Inc.

FAQ

When will Syndax Pharmaceuticals present at the J.P. Morgan Healthcare Conference?

Syndax Pharmaceuticals will present on January 12, 2022, at 08:15 a.m. ET.

How can I watch Syndax's presentation at the J.P. Morgan Healthcare Conference?

You can watch the live webcast of Syndax's presentation on their Investor website.

What are the key cancer therapies developed by Syndax Pharmaceuticals?

Syndax's key therapies include SNDX-5613, axatilimab, and entinostat.

What is the stock symbol for Syndax Pharmaceuticals?

The stock symbol for Syndax Pharmaceuticals is SNDX.